Stockscreener 앱 받기
27.79
3.97%
1.06
시간 외 거래:
27.98
0.19
+0.68%
전일 마감가:
$26.73
열려 있는:
$26.5
하루 거래량:
53,884
Relative Volume:
7.70
시가총액:
$259.99M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+32.21%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$26.01
$28.55
1주일 범위
$19.80
$28.55
52주 변동 폭
$15.80
$28.55
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
203-406-3700
주소
400 ATLANTIC STREET, SUITE 500, STAMFORD
TVRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
27.79 | 259.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com
Form 8-KCurrent report - ADVFN
TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia
TVRD stock soars to 52-week high, reaching $19.01 By Investing.com - Investing.com UK
Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq
TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - Asianet Newsable
Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz
Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com
Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com UK
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India
Cara Therapeutics approves merger and stock plans - Investing.com
Shareholders sue to block Stamford-based Cara Therapeutics’ proposed merger with Houston biopharma firm - Hartford Business Journal
Cara Therapeutics announces merger with Tvardi Therapeutics - Investing.com
Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research - Yahoo Finance
Cara Therapeutics executive Scott Terrillion sells $775 in stock - Investing.com
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.CARA - Business Wire
Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - Investing.com
Cara Therapeutics regains Nasdaq compliance By Investing.com - Investing.com India
Cara Therapeutics regains Nasdaq compliance - Investing.com
Cara Therapeutics Files Certificate of Amendment for Reverse Stock Split and Shares Reduction - Defense World
Cara Therapeutics stock hits 52-week high at $4.26 - Investing.com
Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - GlobeNewswire
Stamford’s Cara Therapeutics to merge with Houston biopharma firm - Hartford Business Journal
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire
STAT3 inhibitors named in Vividion Therapeutics patent - BioWorld MedTech
Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference - Business Wire
Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts - GlobeNewswire
Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors - Business Wire
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma - Business Wire
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs - Business Wire
Tvardi Therapeutics Appoints Michael Wyzga to Board of Directors - citybiz
CARACara Therapeutic Latest Stock News & Market Updates - Stock Titan
Tvardi’s TTI-101 Receives $5 Million in Grant Funding to Support Clinical Trials and Translational Research - Business Wire
Cara Therapeutics (CARA) Stock Price, News & Analysis - MarketBeat
Cara Therapeutics - Crunchbase
Tvardi Therapeutics Inc (TVRD) 재무 분석
Tvardi Therapeutics Inc (TVRD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):